NCT03001609

Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

An Open-Label, Non-Randomized, Single-Center Study to Determine the Absorption, Metabolism and Excretion of A Single Dose [14C] AC0010 in Patients With Advanced NSCLC

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Hangzhou ACEA Pharmaceutical Research Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate Pharmacokinetics parameters of a single dose \[14C\] AC0010 in male Patients With Advanced NSCLC.

Detailed description

The purpose of this study is to investigate the Absorption, Metabolism, Excretion and Pharmacokinetics of a single dose \[14C\] AC0010 in male Patients With Advanced NSCLC.

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

Type	Name	Description
DRUG	AC0010	Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]

Timeline

• Start date: 2016-11-01
• Primary completion: 2017-08-01
• Completion: 2017-09-01
• First posted: 2016-12-23
• Last updated: 2017-10-03

Locations

1 site across 1 country: China